Recent News


5 Apr 2017

Enterprise Therapeutics receives funding from Cystic Fibrosis Trust

Brighton, UK – 05 April, 2017: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for the treatment of cystic fibrosis (CF). [more]

10 Nov 2016

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising

Brighton, UK – November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed a £4 million ($5 million USD) financing. The funding was led by existing investors Epidarex Capital and Imperial Innovations and will be used to accelerate the Company’s three drug discovery projects towards drug candidate selection. [more]

17 Oct 2016

Enterprise Therapeutics appoints Dr John Ford as CEO

Brighton, UK – October 17, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has appointed Dr John Ford as CEO with immediate effect. [more]

20 May 2015

New drug discovery company announces additional funding to tackle chronic respiratory disease

Brighton, Sussex, May 20th 2015 - ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. [more]

12 Feb 2015

World class drug discovery team launches new company to tackle chronic respiratory disease

Brighton, Sussex, February 12th 2015 - ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focussed on novel therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. [more]